Sanofi financially supports adolescent Dupixent users

Patients aged 12 years or older without reimbursement benefit to receive partial coverage on the drug expense

On Jan.

 

11, Sanofi Aventis Korea (President Kay Bae) presented a patient drug expense support program to partially cover the cost of Dupixent Prefilled injection 200 mg (dupilumab) prescribed to adolescent patient with atopic dermatitis.

 

The program aims to contribute in improving the patients’ quality of life by financially supporting the patients with the drug expense, and to allow them to receive the treatment at the right timing.

 

A topical treatment Dupixent is a first ever biologic drug to be indicated to treat adolescent and adult patients aged 12 years or older with moderate to severe atopic dermatitis.

 

After the 300 mg dose, 200 mg dose was also released to the South Korean market in last October.

 

200 mg of Dupixent is injected to an adolescent patient aged 12 years or older with atopic dermatitis but weighing less than 60 kg.

 

Other adolescent patients weighing over 60 kg and adult patients are administered with 300 mg.

 

At the moment, the drug’s National Health Insurance reimbursement covers only the adult patient.

 

As a result, Sanofi has decided to operate a program to cover a part of the adolescent patients’ pharmaceutical expense.

 

Patients prescribed with 200 mg of Dupixent, whose median household income level is under 180 percent.

 

Adolescent patient with severe case of atopic dermatitis has high probability of experiencing negative social interactions, such as bullying and isolation struggling with mental issues like anxiety, inferiority and depression.

 

The company anticipates the financial support program to not only grant access to the treatment, but also give benefit of improving the quality of life.

 

Sanofi Aventis Korea’s Specialty Care business unit CEO Park Hee-kyung commented, “To provide treatment access to adolescent patients with moderate to severe atopic dermatitis, who are neglected from the National Health Insurance benefit, the company has decided to contribute a part of Dupixent 200 mg expense.” The company’s call center and website can be reached for any inquiry on the partial refund and expense support on Dupixent.